During the past decade, Rotkreuzklinikum München-Frauenklinik conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 2 clinical trials were completed, i.e. on average, 200% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Rotkreuzklinikum München-Frauenklinik" are "Breast Neoplasms" (1 trials) and "Metastatic Breast Cancer" (1 trials). Many other conditions were trialed in "Rotkreuzklinikum München-Frauenklinik" in a lesser frequency.

Most popular intervention types in "Rotkreuzklinikum München-Frauenklinik" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "Fulvestrant" (1 trials), "Letrozole" (1 trials), "PD-0332991" (1 trials) and "Seribantumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Rotkreuzklinikum München-Frauenklinik" are 2 trials for "Female" genders.

Currently, there are NaN active trials in "Rotkreuzklinikum München-Frauenklinik". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Rotkreuzklinikum München-Frauenklinik, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Rotkreuzklinikum München-Frauenklinik, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".